Sign up
Pharma Capital
EPIC: CLIN
Market: AIM
52-week High/Low: 1,187.00p / 822.00p
Sector: Pharma & Biotech
Market Cap: 1,048.11M

Clinigen Group plc is a rapidly-growing global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time to improve the quality of people's lives around the world.

The Group consists of three synergistic operations focused in three areas...

Clinigen Group PLC

www.clinigen.co.uk

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Clinigen Group PLC

Clinigen Group PLC Snapshot

Clinigen’s mission is to deliver the right medicine to the right patient at the right time, to improve the quality of people’s lives around the world. There are only three ways for a patient to ethically access a medicine: through a clinical trial, licensed, or unlicensed route and Clinigen are the only company to globally manage access across all three routes.
Clinigen add insight, expertise and value at the critical stages of a product’s lifecycle, supporting pharmaceutical companies and healthcare professionals from clinical trials to full commercialisation. We help to reduce costs in the supply of medicines, achieve more meaningful outcomes and sustained value during commercialisation, and extend the lifetime value of a product.
Clinigen is unique in its ability to operate across all three stages of the pharmaceutical product lifecycle.
Unique Experience
• The combination of businesses are unique and synergistic enabling Clinigen to centrally manage access to treatments for patients across the clinical trial, licensed and unlicensed routes.
• For 30 years, Clinigen have been trusted by industry and healthcare providers the world over to enable access to more innovative medicines, in more countries, for more patients than anyone else.
Ethical Service Delivery
Clinigen is the leading global patient access specialist working to provide ethical and compliant access to unlicensed and licensed medicines for healthcare professionals and their patients with unmet medical need.
All of the services are backed by a team of over 900 dedicated internal subject matter experts, with unsurpassed local market knowledge and global regulatory expertise to ensure ethical and compliant delivery of medicines.

Thought Leadership
Clinigen has pioneered many of the access service offerings commonly used in the industry today and continue to innovate to help patients in need around the world.

Specialist Focus
Clinigen’s sole focus is to enable patient access to medicines in a fully compliant, ethical and efficient manner. The Group exists to help clients and customers meet the evolving demands of global access across the entire product lifecycle.

Global Reach
The Group’s global footprint extends to supplying 111 countries worldwide and the regulatory expertise and local market knowledge can address patient access needs anywhere in the world.

Following the completion of the Link earn-out and subsequent closer integration of Link into the Group, the performance of the business is now reported as three synergistic operations; Clinical Trial Services (‘CTS’), Unlicensed Medicines, and Commercial Medicines. This structure reflects how the Group operates in practice and will allow the Group to develop further the complementary portfolio of businesses worldwide, enhance its ability in providing access to medicines and capitalise on its market-leading positions and expanded geographical footprint.

Clinigen Clinical Trial Services (CTS):

 

CTS is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and IITs. They use global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Find out more about Clinigen Clinical Trial Services.

Unlicensed Medicines:

Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need.

The Group manages early access programs for innovative new medicines. On behalf of pharmaceutical and biotech companies, essential programs are managed that provide access to critical pre-approval medicines for physicians and their patients all over the world. A managed access program is known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’. A managed access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, treatments are delivered quickly, efficiently and, most importantly, ethically.

The Group also provides ‘on-demand’ access globally to medicines which remain unlicensed at the point of care. The Group is the global leader in providing ethical, compliant access to unlicensed or unavailable medicines, meeting the demands of pharmacists and physicians around the world treating patients with unmet medical need.

For pharmacists and physicians, Clinigen provides a ‘go-to’ solution to assist them in accessing medicines for their patients who have no other treatment options available.

For pharmaceutical companies, Clinigen provides solutions to assist them in extending the reach of their products into regions where unmet patient need exists. This could be due to delays in commercial access, a planned lack of commercial presence, product supply shortages or market discontinuations.

Find out more about Unlicensed Medicines.

Commercial Medicines:

Clinigen’s Commercial Medicines operation acquires global rights to niche hospital-only and critical care products and revitalises them back to sustained growth. The products the Group acquires don’t fit into the portfolios of other pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases. The Group specialises in revitalising and ensuring that products will continue to be marketed and distributed responsibly once they have joined the Clinigen portfolio.

The Group also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
The Group also has an ‘unlicensed to licensed’ strategy, where it looks to take unlicensed medicines with commercial potential and licences them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions.

 

Shaun Chilton

Chief Executive Officer

Shaun is the Chief Executive Officer of the Clinigen Group and has the responsibility for the Group achieving its key performance indicators and plays a central role in setting the Group strategy.

Shaun has played a pivotal role in the development of Clinigen, joining the company in January 2012 as Chief Operating Officer, when it was a privately owned company with a turnover of £82m.

He was a key part of the executive team that took Clinigen through IPO in September 2012 and, as deputy CEO in 2015 and then CEO from November 2016, has been a fundamental part of the leadership of the impressive strategic growth of the company from £135m market capitalisation in 2012 to its current position as one of the largest companies on the Alternative Investment Market (AIM) on the London Stock Exchange.

In 2017, Shaun oversaw the largest M&A healthcare deal of the year in the UK with the successful acquisition of Quantum Pharma, in addition to acquiring the largest supplier of unlicensed medicines in Japan, IMMC.

Shaun was awarded the Entrepreneur of the Year Healthcare (Western Europe) in 2017 by the European CEO Awards.

Prior to joining Clinigen, Shaun held senior global strategic, commercial and operational roles at Pfizer, Sanofi, Wolters Kluwer Health and the KnowledgePoint360 Group (now part of UDG Healthcare).

Martin Abell

Chief Financial Officer

Martin joined Clinigen in August 2015 and has over 19 years’ experience working for international, listed companies.

Before Clinigen, Martin worked for Hays plc, Europe’s largest professional recruitment business. He began there as Head of Investor Relations and M&A before becoming Finance Director for the Continental Europe and Rest of World division, which operated across 21 countries with revenues of over £1bn. Prior to that, Martin held several financial roles at the FTSE 100 logistics group, Exel plc (now part of Deutsche Post), including Financial Controller of two of the UK divisions. He is a qualified Chartered Accountant, having trained at PwC in the M&A Transaction Services team.

Terry Walsh

Senior Vice President of Clinical Trial Services

Terry was appointed with the aim of better positioning and strengthening the CTS business in the US and to drive the future development of the business globally.

Terry joined from GSK where he held a number of senior leadership roles in Clinical Trial Supply Chain, Outsourcing and External Drug Discovery, US Managed Markets and Comparator Management. Whilst at GSK, he was seconded to TransCelerate Biopharma Inc., the not-for-profit pharma industry collaboration organisation, where he created the Comparator Purchasing Network. Terry is considered an industry-wide expert in comparator sourcing strategies.

Debra Ainge

Chief Operating Officer

As Chief Operating Officer of Clinigen, Debra oversees the key functions that underpin the Group's central operating platform.

Debra joined Clinigen in 2011 as Head of Project Management in Clinigen Managed Access and has held various roles since then, most recently Director of Corporate Projects where she oversaw the acquisitions and integration of Idis and Link Healthcare. Before joining Clinigen she worked in a variety of research and development roles within AstraZeneca. She has 20 years’ experience in the pharmaceutical sector in both large and small/mid-size organisations including R&D, Speciality and Service Pharma. Debra holds a degree and PhD from Newcastle University, and completed post-doctoral studies at the University of Lausanne.

Benjamin Miny

Senior Vice President of Commercial Medicines

Benjamin was promoted to Senior Vice President of Commercial Medicines following his role within Link Healthcare as Managing Director of South Africa. His role includes both the global management of Clinigen’s Commercial Medicines division and the strategic development of the Group’s unlicensed to licenced strategy. This has already proved successful in South Africa, with Clinigen launching Eisai products and, following the acquisition of Quantum Pharma in 2017, Clinigen seeks to expand these capabilities further.

Jessica Archer

Global Human Resources Director

Jessica has nine years’ experience in Human Resources. She joined Clinigen in 2014 as HR Business Partner and became the Global HR Director in 2016.

Prior to Clinigen, Jessica was HR Manager at Mondelez International (formerly Kraft/Cadbury). She has also worked as an HR Advisor and in Operations Management at Barclays and started her HR career at Sainsbury’s.

A member of the Chartered Institute of Personnel and Development, Jessica has a CIPD Advanced Diploma in HR Management from the University of Manchester and obtained NVQ level 4 in Operations Management during her time at Barclays.

 

 

SIGNIFICANT SHAREHOLDERS

The following were the significant shareholders as at 5 March 2018.

Shareholder
Number of shares held
% issued share capital
AXA Framlington Investment Managers
10,643,695
8.70%
Old Mutual Global Investors 7,443,922 6.09%
Rathbones 6,724,237
5.50%
Octopus Investments 5,188,234 4.24%
Wasatch Advisors 4,996,185 4.09%
Andrew Leaver
  4,253,047
3.48%
Janus Henderson Group 4,185,049 
3.42%
BAE Systems Pensions 4,077,306
3.33%
Neuberger Berman 3,765,089
 3.08%

General enquiries 
Tel:+44 (0) 1283 495 010

Product enquiries
Tel: +44 (0) 1283 494 340

 

HEAD OFFICE

Clinigen, Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW

Tel:+44 (0) 1283 495 010

[email protected]

 

EUROPEAN OFFICE

Clinigen CTS, Pitcairn House, Crown Square, First Avenue, Burton-on-Trent, Staffordshire, DE14 2WW

Tel: +44 (0) 1283 495 010

Fax: +44 (0) 1283 495 011

 

US OFFICE

Clinigen CTS Inc., Three Crescent Drive, Suite 110, Navy Yard Corporate Center, Philadelphia, PA 19112

Tel: +1 (215) 558 7001

Fax: +1 (215) 336 0705

Nominated Advisor
Michael Meade
Numis Securities Limited

The London Stock Exchange Building
10 Paternoster Square
London
EC4M 7LT
Tel: +44 (0) 20 7260 1000

Joint Broker
James Black
Numis Securities Limited

The London Stock Exchange Building
10 Paternoster Square
London
EC4M 7LT
Tel: +44 (0) 20 7260 1000

Joint broker
Marcus Jackson
RBC Capital Markets
Thames Court
One Queenhithe
London
EC4V 3DQ
Tel: +44 (0) 20 7653 4000

Legal Advisor
Addleshaw Goddard LLP

Milton Gate
60 Chiswell Street
London
EC1Y 4AG

Auditors
PriceWaterhouseCoopers LLP

Cornwall Court
19 Cornwall Street
Birmingham
B3 2DT

Registrar
Equiniti Limited

Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA

Media relations
Melanie Toyne-Sewell
Instinctif Partners Limited

65 Gresham Street
London
EC2V 7NQ
Tel: +44 (0) 20 7457 2020
Email: [email protected]

View full CLIN profile View Profile
View All

Market Reports Including CLIN

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.